CAR-T cell therapy is a groundbreaking treatment for certain cancers, but it faces significant challenges in solid tumors and hematological malignancies. Key limitations include severe toxicities, limited tumor infiltration, antigen escape, and an immunosuppressive tumor microenvironment. To address these, innovative strategies are being developed to enhance CAR-T cell efficacy and reduce toxicity. These include engineering CARs with improved antigen binding, optimizing hinge and transmembrane domains, and incorporating co-stimulatory domains like 4-1BB or CD28. Dual or tandem CARs targeting multiple antigens are also being explored to prevent antigen escape. Strategies to improve CAR-T cell trafficking and infiltration include local administration, chemokine receptor modification, and enzymatic degradation of tumor barriers. Combining CAR-T with checkpoint inhibitors or other immunotherapies aims to counteract immunosuppression. Additionally, "off-switches" or suicide genes allow for controlled CAR-T cell depletion in case of toxicity. Despite these advancements, challenges remain in achieving durable responses and minimizing side effects. Ongoing research focuses on refining CAR design, enhancing persistence, and improving safety to make CAR-T therapy more effective and widely applicable for both hematological malignancies and solid tumors.CAR-T cell therapy is a groundbreaking treatment for certain cancers, but it faces significant challenges in solid tumors and hematological malignancies. Key limitations include severe toxicities, limited tumor infiltration, antigen escape, and an immunosuppressive tumor microenvironment. To address these, innovative strategies are being developed to enhance CAR-T cell efficacy and reduce toxicity. These include engineering CARs with improved antigen binding, optimizing hinge and transmembrane domains, and incorporating co-stimulatory domains like 4-1BB or CD28. Dual or tandem CARs targeting multiple antigens are also being explored to prevent antigen escape. Strategies to improve CAR-T cell trafficking and infiltration include local administration, chemokine receptor modification, and enzymatic degradation of tumor barriers. Combining CAR-T with checkpoint inhibitors or other immunotherapies aims to counteract immunosuppression. Additionally, "off-switches" or suicide genes allow for controlled CAR-T cell depletion in case of toxicity. Despite these advancements, challenges remain in achieving durable responses and minimizing side effects. Ongoing research focuses on refining CAR design, enhancing persistence, and improving safety to make CAR-T therapy more effective and widely applicable for both hematological malignancies and solid tumors.